Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
NCT03131206 · Dana-Farber Cancer Institute · PHASE1/PHASE2 · terminated · last registry update 2021-09-27 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study closed due to slow accrual and lack of efficacy.” | Open Targets' class: negative | Registry record, Dana-Farber Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALK in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-04-22Phase 3 first posted: Betta Pharmaceuticals Co., Ltd., Ensartinib + Placebo (NCT05341583)
- 2022-02-11Results posted on the registry: University of Colorado, Denver, Crizotinib (NCT03088930)
- 2022-02-09Results posted on the registry: Pfizer, Avelumab + PF-06463922 (NCT02584634)
- 2022-01-24Phase 3 first posted: Xuanzhu Biopharmaceutical Co., Ltd., XZP-3621 + Crizotinib (NCT05204628)
- 2021-12-27Phase 3 first posted: Hoffmann-La Roche, Alectinib + Entrectinib (NCT05170204)
- 2021-12-17Results posted on the registry: University of Texas Southwestern Medical Center, Ceritinib (NCT02513667)
- 2021-12-14Results posted on the registry: Takeda, Brigatinib (NCT03410108)
- 2021-10-26Results posted on the registry: Pfizer, Lorlatinib (NCT03909971)
- 2021-10-25Results posted on the registry: Ariad Pharmaceuticals, Brigatinib (NCT03535740)
- 2021-10-14Results posted on the registry: Pfizer, PF-02341066 + Rifampin (NCT00585195)
- 2021-08-20Results posted on the registry: Ariad Pharmaceuticals, Brigatinib + Crizotinib (NCT02737501)
- 2021-05-06Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Bevacizumab (NCT02574078)
- 2021-04-01Results posted on the registry: Pfizer, Lorlatinib + Crizotinib (NCT03052608)
- 2020-12-24Results posted on the registry: Novartis Pharmaceuticals, LDK378 (NCT02450903)
- 2020-12-16Results posted on the registry: Novartis Pharmaceuticals, BYL719 + INC280 (NCT02276027)
- 2020-11-17Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., WX-0593 Tablets + crizotinib (NCT04632758)
- 2020-10-27Phase 3 first posted: Hoffmann-La Roche, Entrectinib + Crizotinib (NCT04603807)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision